SDGR
Schrodinger, Inc.
$16.88
+0.49 (+2.99%)
At close · Jul 2
Market Cap
$1.44B
Shares
74,720,724
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.88
Open$16.63
Day$16.55–17.63
52W$10.95–23.75
Avg vol 30d1.4M
Short int10.0M · 13.4% float · 7.6d
Short vol35%
Last earningsMay 5, 2026
DataFeb 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+8% above
+
Price vs 50-day avg
+21% above
◦
RSI (14)
64 · neutral
+
MACD trend
positive
◦
52-week position
46% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $14 › 200d $16 — 200d above 50d
−
Institutional flow
3 of 228 funds reported for Jun 30 · net -993 sh shares · +1 new
−
Insider flow
Net -$1.1M over 90 days · 100% sells
+
Short interest
13.41% of float · ▼ -3.9% MoM · 7.6 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
228 holders — mid 3-yr range
Fundamentals
Excellent
+
Revenue growth
+23% Y/Y
+
Gross margin
56%, contracting
+
EPS growth
+45% Y/Y
+
Free cash flow
$12.5M
+
Balance sheet
net cash $230.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
fiscal year ending December 31, 2026
ACV (annual contract value)
Initiated
$218M – $228M
Drug discovery revenue
Initiated
$55M – $65M
second quarter of 2026
ACV (annual contract value), exclusive of contribution ACV
Initiated
$19M – $23M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+8% above
Bullish
Price vs 50-day avg
+21% above
Bullish
RSI (14)
64 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
46% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow
Distributing
3 of 228 funds reported for Jun 30 · net -993 sh shares · +1 new
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Falling
13.41% of float · ▼ -3.9% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
228 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $11
Now $17 · 46%
52-wk high $24
vs 200-day avg +8%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ACV | $28.4M | first quarter 2026 | — |
| ACV on a trailing four-quarter basis | $201M | first quarter 2026 | — |
| Software gross margin | 69% | first quarter 2026 | — |
| Hosted revenue as percentage of software revenue | 23% | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SDGR
this stock
Schrodinger, Inc.
|
$1.44B | -5.6% | +23.3% | — | 13.4% |
|
VEEV
Veeva Systems Inc
|
$31.31B | -13.7% | +28.1% | 34.2 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.39B | +84.3% | -0.4% | 49.3 | 4.8% |
|
TEM
Tempus AI, Inc.
|
$11.14B | +2.1% | +65.8% | — | 21.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SDGR | +4.6% | +13.1% | -9.3% | +3.9% | -5.6% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +3.2% | +14.3% | -17.3% | +4.2% | -14.8% |